Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Professor Lorraine O'Driscoll

Professor (Pharmacy)
24 WESTLAND ROW


Lorraine O'Driscoll (BSc(Hons, Pharm), MSc(Res, Clin Pharm), MA(Ed), PhD(Biotech), FTCD) Lorraine holds a BSc(Hons), pharmacology; MSc(Res), clinical pharmacology; MA, education; PhD, biotechnology. In 2012, she was elected to Fellowship in TCD. Following her PhD, Lorraine undertook biotechnology/biomedical research for US and EU industry (including Berlex; Archport Ltd-Axonobel; MediSyn Ltd; MedaNova Ltd.) before returning to academic research & teaching. At post-doctoral level, she gained experience at the Dana-Farber Harvard Cancer Institute and University of Miami. Prior to joining TCD in 2008, Lorraine most recently held the position of Senior Research Programme Leader and Lecturer in School of Biotechnology, DCU. Her research group focuses on diagnostic, prognostic and predictive biomarkers; discovering new therapeutic targets; cancer cells communication via exosomes, microvesicles and CTCs; elucidating and circumventing resistance to targets agents and classical chemotherapy; associations between obesity, metabolic syndrome and cancer. She has been a P.I. on 5 cancer clinical trials with ICORG. She is TCD's Principal Investigator on SFI-supported Molecular Therapeutics for Cancer Ireland; Strand Leader of Irish Cancer Society-supported Breast-PREDICT; and P.I. and Chair, H2020-supported European Network Cooperation in Science and Technology focussed on Exosomes & Microvesicles in Health & Disease which brings together researchers from 27 European countries, 3 US universities, Australia and 7 industry partners. In 2017, she was awarded approx. €4,000,000 as Director of a H2020 ITN aimed at training 15 PhD students in TRAIN-EV i.e. training in extracellular vesicles: for benefit in health and disease. She has developed tailored courses for academia (e.g. FEBS), semi-state bodies (e.g. IDA) and industry. Her graduates and mentees are now employed at NIH; Pfizer; Amgen; Leo; Roche; AstraZeneca; ICON plc; 2 are entrepreneurs/company CEOs; 2 are Managers of Research Centres; others hold lecturing and research posts in academia.
  Apoptosis   Apoptosis, molecular control   Bioinformatics   Biology   Biology and therapy of myeloma   Biomedical sciences   Breast cancer   Cancer genetics and cell biology including metastasis   Cell and tissue development   Cell and tissue maintenance, repair and ageing   Clinical research, trials   Diabetes and diabetic complications   Diagnostics   DNA transcription and translation   Drug development and evaluation   Drug discovery, profiling, targeting   Embryonic development   Endocrine function and disease   Gene targeting in breast cancer   Gene therapy   Gene transcription in human cancer   Human genetics   Immunoassays   In vitro testing, trial methods   Medical Sciences, Research   Membrane and protein trafficking   Multiple Myeloma   Oncogenes, apoptosis and tumour development   Pathology   Prostate cancer   Regulatory methods of gene expression   RNA processing, stability and degradation   Stem Cell biology and hematopoiesis   Therapeutic and Clinical oncology
 Extracellular Vesicles Promoted Regenerative Osseointegration (EVPRO)
 Marie Keating Foundation PhD Scholarship at Trinity College Dublin
 Molecular Therapeutics for Cancer
 New Diagnostic and Prognostic Biomarkers for Age-Related Macular Degeneration
 Characterisation of 2 Novel mRNAs Present in Breast Tumours - but not Normal Breast Tissue - with potential as Therapeutic Targets & Diagnostic/Prognostic Biomarkers.

Page 1 of 4
Details Date
Chair, Career Development Sub-Committee, FHS Athena Swan Application 2018
Editorial Board Member, Anticancer Research 2009
Editorial Board Member, J. Extracell. Ves. 2013
Editorial Board Member, PeerJ 2012
Guest-Editor of book volume of Current Cancer Drug Targets entitled "Mechanisms of Cancer Drug Sensitivity & Resistance: A Translational Approach" 2009
Guest-Edition of Methods in Molecular Biology: Gene Expression Profiling 2009
Research Specialist: All Ireland Clinical Oncology Research Group/Cancer Trials Ireland (& Principal Investigator on Phase I & II cancer clinical trials) 2005
Appointed as Strand Leader, Irish Cancer Society (ICS)-funded national virtual research centre Breast-Predict 2013
Cancer Theme Steering Committee member, Trinity College Dublin 2012
Management Committee member, Irish Cancer Society (ICS)-funded national virtual cancer research centre Breast-Predict 2013
Mentor, Career path Development, University College Los Angeles (UCLA) 2011
Founding Director, TRAIN-EV training in extracellular vesicles: for benefit in health and disease. 2017
Management Committee member, Science Foundation Ireland-funded national virtual cancer research centre Molecular Therapeutics for Cancer Ireland 2009
Strategic Advisory Board Member, Midatech Ltd, Oxford 2014
Hospital Professional Awards: Judguing Panel Member 2014
External Examiner to Aarhus University postgraduate degree programmes 2010
External Examinder for 29 PhD candidates including studenst in: Oxford Univeristy, Cambridge University, Aarhus University, Edinburgh University, Cardiff University, University College London, Queen's University Belfast, Royal College of Surgeons of Ireland, National University of Ireland Galway, University College Dublin, Univeristy College Cork 2005
External Examiner/Panel Member to Athlone Institute of Technology for Higher Education and Training Awards Council (HETAC) 2006
Examiner (Report and Site Visit) for Enterprise Ireland Applied Research Capability award to Dundalk Institute of Technology 2013
Frequently review for journals incl. Oncogene, Eur. J. Cancer, J. Medical Virol., Tissue Eng., J. Histochem. Cytochem., Stem Cells, Anticancer Res., Exp. Opin. Drug Discovery, BMC Development Biology, Diabetes, Obesity & Metabolism, Cancer Detect. Prevent., The Review of Diabetes Studies, Cancer Genomics & Proteomics, Differentiation, FEBS Lett., Exp. Opin. Mol. Diag., Eur. J. Pharmaceutical Sci, Experimental Haematol., Personalized Medicine, Circulation Res., Biochemica Medica, Cancer, Eur. J. Pharmacol., Leukaemia Res., Biochem. Pharmacol., Exp. Opin. Therap. Targets, J. Pharmacy & Pharmacol., Brit. J. Dermatol., Clin. Chem., BBA Cancer, Cancer Res., Nature, Nature Medicine, The Lancet 2001
Editorial Board Member, Molecular Biotechnology 2010
Editorial Board Member, BMC Cancer å 2011
Invited Role Model, Inspiring Leadership - Leadership Foundation for Higher Education (Aurora), Ireland and UK 2016
Editorial Board Member, Journal of Biomarkers 2012
Management Committee member, H2020-funded cooperation in science and technology: Delivery of Antisense RNA Therapeutics 2018
Editorial Board Member for Encyclopaedia of Bioscience Frontier in Bioscience 2007
Management Committee member, H2020-funded cooperation in science and technology: Identifying Biomarkers through Translational Research for Prevention and Stratifictaion of Cancer 2018
Secretary to Science and Meetings Committee, ISEV 2018
Guest-Edition of Methods in Molecular Biology: Gene Expression Profiling - 2nd Edition 2018
Editorial Board Member for Cancer Genomics & Proteomics 2006
Details Date From Date To
Elected Member of the Board of Directors, International Society for Extracellular Vesicles (ISEV) 2018
Board Member of the National Institute for Cellular Biotechnology 2002 2008
Member of the National Institute for Cellular Biotechnology Scientific Advisory Board 2002 2008
Elected Member on Dublin City University's Research Advisory Panel 2002 2008
Elected Member on Dublin City University's Faculty of Science & Health Research Committee 2003 2008
Member of British Pharmacological Society 2016 present
Member, European Assoication for Cancer Research (EACR) 2008
Member, American Society for Cancer Research (AACR) 2007
Member, European Society for Medical Oncology (ESMO) 2006
Member, American Society for Clinical Oncology (ASCO) 2007
Founding Committee Member, Irish Association of Pharmacologists (IAP) 2016 present
Founding Chair, European Network on Microvesicles and Exosomes in Health and Disease 2013 present
Invited Member of Irish Cancer Society (ICS) Research Capacity Building Committee 2011 2013
Invited Member of the International Institute of Anticancer Research (IIAR) Scientific Advisory Board 2006 present
Deputy-President of the Irish Branch of the European Tissue Culture Society (ETCS) 2005 2010
Director, Irish Association for Cancer Research (IACR) 2008 2014
Member of the European Association for Cancer Research (EACR) 2006 present
Member of Irish Network of Stem-Cell Investigators (INNSI) 2004 2010
Thery C,...O'Driscoll L.. (alphabetical order).., Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines, J. Extracell. Vesicles, 2019, Notes: [https://doi.org/10.1080/20013078.2018.1535750 ], Journal Article, PUBLISHED  URL
McNamee N, O'Driscoll L, Extracellular vesicles and anti-cancer drug resistance, BBA Cancer, 1870, (2), 2018, p123 - 136, Journal Article, PUBLISHED  DOI  URL
Lowry MC, O'Driscoll L, Can hi-jacking hypoxia inhibit extracellular vesicles in cancer?, Drug Discovery Today, 23, (6), 2018, p1267 - 1273, Journal Article, PUBLISHED  DOI  URL
Eustace AJ, Conlon NT, McDermott MSJ, Browne BC, O'Leary P, Holmes FA, Espina V, Liotta LA, O'Shaughnessy J, Gallagher C, O'Driscoll L, Rani S, Madden SF, O'Brien NA, Ginther C, Slamon D, Walsh N, Gallagher WM, Zagozdzon R, Watson WR, O'Donovan N, Crown J., Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL., BMC Cancer, 18, (1), 2018, Notes: [doi: 10.1186/s12885-018-4852-1], Journal Article, PUBLISHED  DOI  URL
O'Neill S, Larsen MB, Gregersen S, Hermansen K, O'Driscoll L., miR-758-3p: a blood-based biomarker that's influence on the expression of CERP/ABCA1 may contribute to the progression of obesity to metabolic syndrome., Oncotarget, 9, (10), 2018, p9379 - 9390, Journal Article, PUBLISHED  TARA - Full Text  DOI  URL
Lowry MC, Breslin S, O'Driscoll L., Investigating the roles of macrophage colony-stimulating factor (CSF1) and carbonic anhydrase 9 (CAIX) in neratinib-resistant HER2+ breast cancer cell lines and extracellular vesicles., J. Extracell. Vesicles., 7, (1), 2018, pp23 - 23, Published Abstract, PUBLISHED  DOI  URL
Conlon NT, Lowry MC, Breslin S, O'Driscoll L, Eustace AJ, Crown J, O'Donovan N, Collins DM., Src inhibition overcomes neratinib-resistance in HER2-positive breast cancer., Expt. Mol. Therapeutics., Amer. Assoc. for Cancer Res. (AACR), Chicago, US, 78, (13), 2018, pp1834 - 1835, Published Abstract, PUBLISHED
MicroRNA Profiling of Exosomes in, editor(s)Rani S , Methods in Molecular Biology, New York, Springer, 2017, pp37 - 46, [Daly M, O'Driscoll L], Book Chapter, PUBLISHED  TARA - Full Text  DOI  URL
Profiling Circulating miRNAs from the Plasma of Individuals with Metabolic Syndrome in, editor(s)Rani S , Meth. Mol. Biol., New York, Springer, 2017, pp141 - 149, [O'Neill S, O'Driscoll L], Book Chapter, PUBLISHED  TARA - Full Text  DOI  URL
O'Driscoll L, Stoorvogel W, Thery C, Buzas E, Nazarenko I, Siljander P, Yanez-Mo M, Fais S, Giebel B, Yliperttula M, European Network on Microvesicles and Exosomes in Health and Disease, European Journal of Pharmaceutical Sciences, 98, 2017, p1 - 3, Journal Article, PUBLISHED  DOI  URL
  

Page 1 of 16
EU Commission/H2020, 'European Network on Microvesicles and Exosomes in Health & Disease', https://youtu.be/TmQBS5rPyEY, 2018, -, Broadcast, PUBLISHED
O'Driscoll L, Keynotes Speaker: Exosomes and Ectosomes - friends & foes in cancer?, Dublin City University Research Day, Dublin City University, 26 January, 2018, Invited Talk, PRESENTED
O'Driscoll L, Characterisation and analysis of exosomes/extracellular vesicles, American Physiological Society: President's Symposium Series, San Diego, US, 22 April, 2018, Invited Talk, PRESENTED
O'Driscoll L, Training in Extracellular Vesicles: for benefit in Health & Disease, International Society for Extracellular Vesicles (ISEV) 2018, Barcelona, Spain, 3 May, 2018, Invited Talk, PRESENTED
O'Driscoll L., Interview by HBM-LS (Lonza), 2018, -, Notes: [http://www.hansabiomed.eu/index.php/lorraine-o-driscoll], Miscellaneous, PUBLISHED
Lowry MC, Breslin S, Conlon NT, Collins D, Eustace A, Crown J, Maher S, O'Sullivan J, O'Driscoll L, Investigating the role of CAIX in the mechanism of HER2-targeted drug resistance in breast cancer cells and extracellular vesicles , Breast-Predict showcase, UCD, Dublin, 17 October, 2018, Oral Presentation, PRESENTED
Lowry MC, Breslin S, O'Driscoll, Investigating the role of CSF-1 and CAIX in neratinib-resistant HER2+ breast cancer cell lines and extracellular vesicles, International Society for Extracellular Vesicles (ISEV) 2018, Barcelona, Spain, 2-6 May, 2018, Oral Presentation, PRESENTED
O'Driscoll L, Microvesicles and Exosomes in Health and Disease, International Society for Extracellular Vesicles (ISEV) 2017, Toronto, Canada, 17-21 May, 2017, Invited Talk, PRESENTED
O'Driscoll L, Extracellular Vesicles (EVs) and Therapy, 24th Meeting of the EAU Section of Urological Research (ESUR), Institut Curie, Paris, France, 13 October, 2017, Invited Talk, PRESENTED
O'Driscoll L, Exosomes and Ectosomes: important Players in the Liquid Biopsy, Inaugural Cancer Research Club, University College Dublin, 21 November, 2017, Invited Talk, PRESENTED

  

Page 1 of 13
Award Date
Elected Fellow of Trinity College Dublin 2012
MA (jure oficii) 2012
Bi-directional translational research; cancer research; diagnostic biomarkers; prognostic biomarkers; predictive markers; novel therapeutic targets; targeted therapies; pipeline drugs; monoclonal antibodies; small molecules; clinical and industry collaborations; breast cancer; lung cancer; prostate cancer; melanoma; multiple myeloma; circulating tumour cells (CTCs); multi-drug resistance; stem cells; differentiation; diabetes; islet transplants; microarrays; proteomics; mRNAs; microRNAs (miRNAs); clinical trials